GU Cancers Symposium 2013 - Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer: Immune results, by Emmanuel S. Antonarakis, MD, et al

ORLANDO, FL, USA (UroToday.com) - Sipuleucel-T is an autologous cellular immunotherapy that targets prostatic acid phosphatase (PAP) and is FDA-approved for the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing of ADT and sipuleucel-T to maximize immune and clinical responses is unknown.

Here, we report interim data from a phase 2 trial evaluating the sequencing of sipuleucel-T and ADT by examining immune parameters in patients with BRPC at high risk for metastases...Click here to enlarge and view the poster.

 

optimal sequencing sip and adt thumb 
                                (Click thumbnail to enlarge poster)

 

Read session highlights by a UroToday.com medical editor

 

Presented by Emmanuel S. Antonarakis,1 Adam S. Kibel,2 Robert C. Tyler,3 Candice McCoy,3 Yang Wang,3 Nadeem A. Sheikh,3 and Charles G. Drake1 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

1Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; 2Dana-Farber Cancer Institute, Boston, MA; 3Dendreon Corporation, Seattle, WA



gucancerssympalt thumb



View Full 2013 GU Cancers Symposium Coverage



 



 

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe